Special Issue

Novel Biomarkers and Diagnostic Methods of Cardiovascular Disease

Message from the Guest Editors

The understanding of cardiovascular diseases and their management has changed dramatically over the last 30 years with the identification of various pathways and the successful development of effective therapies that target them. This has led to a concomitant reduction in mortality and morbidity and an improvement in the functional capacity and quality of life of these patients. However, there are still major unmet needs in the management of these diseases; they continue to be the number one cause of death globally with the social and economic impact remaining largely unchanged. Therefore, it is of utmost importance to identify novel biomarkers and diagnostic methods through endeavors in basic research areas to better understand the disease mechanisms, identify novel biomarkers for early intervention, improved diagnosis, and experimental medicine for better disease management. This Special Issue in the *Journal of Personalized Medicine* will encompass both review and original research articles by experts in the field.

Guest Editors

Dr. Estefanía Tarazón

1. Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain
2. Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), Madrid, Spain

Dr. Esther Rosello-Lleti

Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain

Deadline for manuscript submissions

closed (10 December 2022)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).